Membranous nephropathy tacrolimus needs to be gradually reduced, the specific should be combined with the actual situation of the patient to decide, in general, after 6 months of use if complete or partial remission is achieved and no tacrolimus-related nephrotoxicity occurs, it is recommended that the dose of tacrolimus will be reduced to 50% of the initial dose within 4-8 weeks, the full course of treatment for at least 12 months. Patients with membranous nephropathy taking tacrolimus for a certain course of treatment, approximately 6 months, are recommended to discontinue tacrolimus if complete or partial remission is not achieved after 6 months of tacrolimus treatment. If complete or partial remission is achieved and no tacrolimus-related nephrotoxicity occurs, it is recommended that the tacrolimus dose be reduced to 50% of the initial dose within 4 to 8 weeks for a full course of at least 12 months; if an unexplained elevation of blood creatinine (>20%) occurs during treatment, be careful to test tacrolimus blood levels. Tacrolimus may be used as an immunosuppressant, mainly utilizing the efficacy produced by binding to cytosolic proteins, and may be commonly used in membranous nephropathy or as adjunctive therapy after kidney transplantation. Long-term use of tacrolimus may cause renal insufficiency or trigger adverse reactions such as hypertension; it is contraindicated for those who are allergic to the drug components, and used with caution for those who have congestive heart failure and cardiac arrhythmia. Membranous nephropathy patients, it is recommended to consult a regular hospital in time and standardize the treatment under the guidance of a professional physician.